| SCAP vs HIFU for Recurrent Prostate Cancer After Radiation Therapy (NCT05044754) | University Hospital Virgen de las Nieves | 2021-10-01 |
| Tumor Microenvironment Analysis of Prostate Cancer Metastasis (NCT05304858) | Columbia University | 2021-09-15 |
| Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer (NCT05077098) | Mark Stein | 2021-08-12 |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (NCT04787744) | VA Office of Research and Development | 2021-07-01 |
| Salvage Cryotherapy for Recurrent Prostate Cancer After Radiation Therapy (NCT04891536) | Ignacio Puche Sanz | 2021-05-01 |
| Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer. (NCT04644822) | Centre for Probe Development and Commercialization | 2020-12-21 |
| Nivolumab in Biochemically Recurrent dMMR Prostate Cancer (NCT04019964) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2020-01-13 |
| PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores (NCT03495427) | H. Lee Moffitt Cancer Center and Research Institute | 2019-12-18 |
| Impact of Atorvastatin on Prostate Cancer Progression During ADT (NCT04026230) | Tampere University Hospital | 2019-08-15 |
| Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy (NCT03496805) | Wake Forest University Health Sciences | 2019-01-29 |
| PSMA-PET Registry for Recurrent Prostate Cancer (NCT03718260) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2018-09-27 |
| Partial Prostate Salvage High Dose Rate Brachytherapy (NCT03246802) | British Columbia Cancer Agency | 2018-01-01 |
| Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System (NCT03067051) | SpectraCure AB | 2017-03-21 |
| Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer (NCT02169063) | University of Washington | 2015-12-01 |
| Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (NCT02278185) | University of Colorado, Denver | 2015-11-11 |
| Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer (NCT02217709) | University of Southern California | 2014-09-08 |
| Vigorous or Moderate Exercise in Enhancing Active Surveillance in Patients With Localized Prostate Cancer (NCT02179762) | Case Comprehensive Cancer Center | 2014-08-09 |
| Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer (NCT02184533) | Stanford University | 2014-07-01 |
| LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer (NCT02058706) | Barbara Ann Karmanos Cancer Institute | 2014-05-01 |
| Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer (NCT02049190) | Arno Therapeutics | 2014-02-01 |
| Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer (NCT01949337) | Alliance for Clinical Trials in Oncology | 2014-01-22 |
| Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery (NCT01912820) | Jonsson Comprehensive Cancer Center | 2014-01-01 |
| Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer (NCT02012296) | University of Chicago | 2013-12-13 |
| Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer (NCT01967862) | City of Hope Medical Center | 2013-12-01 |
| Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery (NCT01923506) | City of Hope Medical Center | 2013-11-25 |
| FACBC for Recurrent Prostate Cancer (NCT01808222) | David M. Schuster, MD | 2013-11-01 |
| Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01866423) | University of Southern California | 2013-10-25 |
| Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (NCT01848067) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-08-14 |
| Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01913015) | OHSU Knight Cancer Institute | 2013-07-01 |
| Cabozantinib in Men With Castration-Resistant Prostate Cancer (NCT01703065) | University of Washington | 2013-06-18 |
| Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer (NCT01807065) | City of Hope Medical Center | 2013-06-07 |
| Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy (NCT02050906) | Ohio State University Comprehensive Cancer Center | 2013-05-21 |
| Brachytherapy for Recurrent Prostate Cancer (NCT01956058) | Centre Georges Francois Leclerc | 2013-03-26 |
| Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer (NCT01812668) | Barbara Ann Karmanos Cancer Institute | 2013-03-01 |
| Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer (NCT01802346) | University of Southern California | 2013-01-29 |
| Bipolar Androgen-based Therapy for Prostate Cancer (BAT) (NCT01750398) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2013-01-01 |
| High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer (NCT01655836) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-10-04 |
| Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01685125) | University of Southern California | 2012-09-01 |
| High-Dose Stereotactic Radiation for Prostate Cancer (NCT01664130) | Case Comprehensive Cancer Center | 2012-07-01 |
| Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel (NCT01469338) | University of Southern California | 2012-07-01 |
| Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer (NCT01599793) | University of Chicago | 2012-05-01 |
| Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy (NCT01555632) | University of Nebraska | 2012-03-01 |
| Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer (NCT01859689) | Jonsson Comprehensive Cancer Center | 2012-03-01 |
| Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01498978) | OHSU Knight Cancer Institute | 2012-02-06 |
| Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer (NCT01533246) | National Cancer Institute (NCI) | 2012-02-01 |
| Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer (NCT01174199) | Roswell Park Cancer Institute | 2012-02-01 |
| Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery (NCT01433913) | National Cancer Institute (NCI) | 2011-11-01 |
| Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01468532) | Barbara Ann Karmanos Cancer Institute | 2011-10-01 |
| Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer (NCT01054079) | Wake Forest University Health Sciences | 2011-09-01 |
| Genistein in Treating Patients With Prostate Cancer (NCT01126879) | Northwestern University | 2011-02-03 |
| Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients (NCT01882985) | University of California, Irvine | 2010-12-01 |
| Saracatinib in Treating Patients With Prostate Cancer (NCT01267266) | National Cancer Institute (NCI) | 2010-12-01 |
| Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01240629) | University of Southern California | 2010-11-02 |
| Sulforaphane in Treating Patients With Recurrent Prostate Cancer (NCT01228084) | OHSU Knight Cancer Institute | 2010-11-01 |
| Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel (NCT01260688) | National Cancer Institute (NCI) | 2010-10-01 |
| Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer (NCT01200810) | National Cancer Institute (NCI) | 2010-08-01 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (NCT01155258) | University of Southern California | 2010-06-01 |
| Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer (NCT01093183) | University of Nebraska | 2010-03-04 |
| Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer (NCT00956163) | National Cancer Institute (NCI) | 2010-03-01 |
| Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen (NCT01682941) | Ohio State University Comprehensive Cancer Center | 2009-10-01 |
| Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients (NCT00879619) | John P. Fruehauf | 2009-07-01 |
| CyberKnife Radiosurgery for Locally Recurrent Prostate CA (NCT00851916) | CyberKnife Centers of San Diego | 2009-02-01 |
| A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial) (NCT00772317) | SonaCare Medical | 2008-07-01 |
| Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21 (NCT00583752) | David M Lubaroff | 2007-12-01 |
| Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer (NCT00512668) | National Cancer Institute (NCI) | 2007-09-01 |
| AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00513071) | National Cancer Institute (NCI) | 2007-08-01 |
| Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer (NCT00570700) | University of California, Irvine | 2007-07-01 |
| Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy (NCT01656304) | Barbara Ann Karmanos Cancer Institute | 2007-05-01 |
| Salvage Cryotherapy in Recurrent Prostate Cancer (NCT00824928) | University of Colorado, Denver | 2007-01-01 |
| Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00337077) | National Cancer Institute (NCI) | 2006-11-01 |
| MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy (NCT00775866) | University Health Network, Toronto | 2006-10-01 |
| Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer (NCT01338792) | University of Southern California | 2006-06-01 |
| Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy (NCT00331344) | National Cancer Institute (NCI) | 2006-04-01 |
| Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer (NCT00330161) | National Cancer Institute (NCI) | 2006-03-01 |
| Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer (NCT00103194) | National Cancer Institute (NCI) | 2005-09-01 |
| Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00110214) | National Cancer Institute (NCI) | 2005-04-01 |
| SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel (NCT00096499) | National Cancer Institute (NCI) | 2005-04-01 |
| Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer (NCT00109811) | National Cancer Institute (NCI) | 2005-03-01 |
| 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy (NCT00118092) | National Cancer Institute (NCI) | 2005-01-01 |
| Cilengitide in Treating Patients With Prostate Cancer (NCT00121238) | National Cancer Institute (NCI) | 2005-01-01 |
| Cilengitide in Treating Patients With Metastatic Prostate Cancer (NCT00103337) | National Cancer Institute (NCI) | 2005-01-01 |
| Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer (NCT00095667) | National Cancer Institute (NCI) | 2004-11-01 |
| Ixabepilone in Treating Patients With Metastatic Prostate Cancer (NCT00087139) | National Cancer Institute (NCI) | 2004-09-01 |
| Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer (NCT00080899) | National Cancer Institute (NCI) | 2004-06-01 |
| Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy (NCT02452307) | University Hospital Tuebingen | 2004-04-01 |
| Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer (NCT00058084) | National Cancer Institute (NCI) | 2003-03-01 |
| Perifosine in Treating Patients With Recurrent Prostate Cancer (NCT00058214) | National Cancer Institute (NCI) | 2003-03-01 |
| Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors (NCT00058253) | National Cancer Institute (NCI) | 2003-02-01 |
| BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy (NCT00040755) | National Cancer Institute (NCI) | 2002-05-01 |
| Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer (NCT00039104) | National Cancer Institute (NCI) | 2002-04-01 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction (NCT00030498) | National Cancer Institute (NCI) | 2001-12-01 |
| Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer (NCT00016107) | National Cancer Institute (NCI) | 2001-06-01 |
| Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer (NCT00005067) | National Cancer Institute (NCI) | 2000-02-01 |
| Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) (NCT00005039) | National Cancer Institute (NCI) | 2000-01-01 |
| Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer (NCT00020046) | National Institutes of Health Clinical Center (CC) | 1999-12-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |
| Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer (NCT00019695) | National Cancer Institute (NCI) | 1999-03-01 |
| Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography (NCT02531672) | Memorial Sloan Kettering Cancer Center | |
| Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer (NCT00003517) | Burzynski Research Institute | |